

THU0579

**“EVOLVING THE MANAGEMENT OF RA” PROGRAMME: EDUCATIONAL TOOLS TO SUPPORT DAILY PRACTICE**

G. R. Burmester<sup>1</sup>, J. M. Alvaro-Gracia<sup>2</sup>, N. Betteridge<sup>3</sup>, J. Calvo<sup>4</sup>, B. Combe<sup>5</sup>, P. Durez<sup>6</sup>, R. J. O. Ferreira<sup>7</sup>, B. Fautrel<sup>8</sup>, A. Iagnocco<sup>9</sup>, C. Montecucco<sup>10</sup>, M. Østergaard<sup>11</sup>, S. Ramiro<sup>12</sup>, A. Rubbert-Roth<sup>13</sup>, T. Stamm<sup>14</sup>, Z. Szekanecz<sup>15</sup>, P. C. Taylor<sup>16</sup>, M. Van de Laar<sup>17</sup>. <sup>1</sup>Charité, Berlin, Germany; <sup>2</sup>Hospital Universitario Gregorio Marañón, Madrid, Spain; <sup>3</sup>Neil Betteridge Associates, London, United Kingdom; <sup>4</sup>Hospital Universitario Araba, Vitoria-Gasteiz, Spain; <sup>5</sup>University of Montpellier, Montpellier, France; <sup>6</sup>UCL-Saint Luc, Woluwe-Saint-Lambert, United Kingdom; <sup>7</sup>CHUC, Coimbra, Portugal; <sup>8</sup>Sorbonne University, Paris, France; <sup>9</sup>Università di Torino, Turin, Italy; <sup>10</sup>Policlinico San Matteo, Pavia, Italy; <sup>11</sup>University of Copenhagen, Copenhagen, Denmark; <sup>12</sup>LUMC, Leiden, Netherlands; <sup>13</sup>Kantonsspital St. Gallen, St. Gallen, Switzerland; <sup>14</sup>Medizinische Universität Wien, Vienna, Austria; <sup>15</sup>University of Debrecen, Debrecen, Hungary; <sup>16</sup>University of Oxford, Oxford, United Kingdom; <sup>17</sup>MST, Enschede, Netherlands

**Background:** The eRA (evolving the management of RA) programme was initiated in Europe to provide practical educational tools that address unmet needs in the management of rheumatoid arthritis (RA). Several eRA tools – covering early access to care, management of comorbidities, treat-to-target strategies, and patient empowerment – are available to the rheumatology community. Through ongoing activities, the eRA Steering Committee (SC) identified a need for tools on non-pharmacological management of RA.

**Objectives:** To improve accessibility to eRA tools for rheumatology professionals; to review the evidence base of non-pharmacological interventions to create new eRA resources that may support management decisions.

**Methods:** A web platform providing information on eRA programme and tools was developed in 2019. The platform collects survey-based metrics to quantify perception of eRA and use of eRA tools in clinical practice. Platform and tools are translated to further support access and use across Europe.

To address unmet needs in non-pharmacological patient management, the eRA SC reviewed the core literature on agreed priority interventions, including physical activity, diet, patient education and self-management, psychosocial interventions, occupational therapy and orthotics, hand exercises, and hydrotherapy/balneotherapy. Available evidence for each intervention was assessed and graded according to the Oxford Centre for Evidence-based Medicine Levels of Evidence.

**Results:** The eRA web platform is now live in 3 countries ([www.evolutingthemanagementofRA.com](http://www.evolutingthemanagementofRA.com)), hosting translated copies of the eRA tools, with additional countries launching throughout 2020.

From a review of core literature on non-pharmacological interventions, the eRA SC determined that strong evidence exists to support use of physical activity, patient education and self-management, psychosocial interventions, and occupational therapy and orthotics. Evidence was lacking or conflicting for diet and nutrition, hand exercises, and balneotherapy/hydrotherapy. A set of educational slides was produced by the eRA SC to summarise the evidence (Fig. 1) and provide top-line guidance on use of interventions in practice that should engage relevant members of the multi-disciplinary team. These slides are available through eRA dissemination activities.

**Conclusion:** The eRA programme content is now freely available to health care professionals in several countries on a web platform, supported by translations of the eRA tools. An additional slide set on non-pharmacological management serves to further increase the practical guidance of this programme's educational offering.

Intervention	Strength*	Evidence summary
Physical activity	Strong evidence	Resistance and/or aerobic exercise has positive effects on several outcomes (e.g. strength, function). Some types of physical activity present with inconsistent evidence (e.g. Tai Chi, yoga) regarding their effects on outcomes.
Occupational therapy interventions and orthotics	Strong evidence	Occupational therapy interventions have positive effects on function. Podiatry interventions have positive effects on pain, but evidence is inconsistent regarding effects on function. Wrist splints may have positive effects on pain, but there is insufficient evidence regarding their effects on function.
Patient education and self-management interventions	Strong evidence	Patient education has positive effects on coping ability (e.g. with pain) and adherence (e.g. to supportive interventions). For education, there is inconsistent evidence regarding the long-term benefits and effects on self-efficacy. For self-management programmes, there is inconsistent evidence regarding effects on function.
Psychosocial interventions	Strong evidence	Psychosocial interventions have positive effects on many outcomes when used as an adjunct to pharmacological management, but evidence is inconsistent regarding long-term effects. Cognitive-behaviour therapy has positive effects on depression and fatigue.
Hand exercises	Additional evidence needed	Additional high-quality evidence is required before findings can translate into daily practice in RA management.
Nutrition and diet	Additional evidence needed	Additional high-quality evidence is required before findings can translate into daily practice in RA management. NOTE: Healthy diet and weight control are supported by EULAR recommendations and national guidelines should be followed.
Balneotherapy / hydrotherapy	Additional evidence needed	Additional high-quality evidence is required before findings can translate into daily practice in RA management.

Fig. 1. Summary of evidence for non-pharmacological interventions

**Acknowledgments:** The eRA programme is funded by Sanofi Genzyme. Programme direction and content creation are driven by an independent Steering Committee

**Disclosure of Interests:** Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Jose-Maria Alvaro-Gracia Grant/research support from: Abbvie, Elli-Lilly, MSD, Novartis, Pfizer, Consultant of: Abbvie, BMS, Janssen-Cilag, Elli-Lilly,

MSD, Novartis, Pfizer, Sanofi, Tigenix, Roche, UCB, Paid instructor for: Elli-Lilly, Pfizer, Roche, Speakers bureau: Abbvie, BMS, Janssen-Cilag, Elli-Lilly, Gedeon Richter, MSD, Novartis, Pfizer, Sanofi, Tigenix, Roche, UCB, Neil Betteridge Consultant of: Amgen, Eli Lilly and Company, Grunenthal, GSK, Sanofi Genzyme, Jaime Calvo Grant/research support from: Lilly, UCB, Consultant of: Abbvie, Jansen, Celgene, Bernard Combe Grant/research support from: Novartis, Pfizer, Roche-Chugai, Consultant of: AbbVie; Gilead Sciences, Inc.; Janssen; Eli Lilly and Company; Pfizer; Roche-Chugai; Sanofi, Speakers bureau: Bristol-Myers Squibb; Gilead Sciences, Inc.; Eli Lilly and Company; Merck Sharp & Dohme; Pfizer; Roche-Chugai; UCB, Patrick Durez Speakers bureau: AbbVie, Bristol-Myers Squibb, Celltrion, Eli Lilly, Pfizer, Sanofi, Ricardo J. O. Ferreira Grant/research support from: Abbvie, Consultant of: Sanofi Genzyme, Amgen, MSD, Paid instructor for: UCB, Bruno Fautrel Grant/research support from: AbbVie, Lilly, MSD, Pfizer, Consultant of: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Lilly, Janssen, Medac MSD France, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi Aventis, SOBI and UCB, Annamaria Iagnocco Grant/research support from: Abbvie, MSD and Alfasigma, Consultant of: AbbVie, Abiogen, Alfasigma, Biogen, BMS, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Sanofi and Sanofi Genzyme, Speakers bureau: AbbVie, Alfasigma, BMS, Eli-Lilly, Janssen, MSD, Novartis, Sanofi, Carlomaurizio Montecucco: None declared, Mikkel Østergaard Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Merck, and Novartis, Consultant of: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, Sofia Ramiro Grant/research support from: MSD, Consultant of: Abbvie, Lilly, Novartis, Sanofi Genzyme, Speakers bureau: Lilly, MSD, Novartis, Andrea Rubbert-Roth Consultant of: Abbvie, BMS, Chugai, Pfizer, Roche, Janssen, Lilly, Sanofi, Amgen, Novartis, Tanja Stamm Grant/research support from: AbbVie, Roche, Consultant of: AbbVie, Sanofi Genzyme, Speakers bureau: AbbVie, Roche, Sanofi, Zoltán Szekanecz Grant/research support from: Pfizer, UCB, Consultant of: Sanofi, MSD, Abbvie, Pfizer, Roche, Novartis, Lilly, Gedeon Richter, Amgen, Peter C. Taylor Grant/research support from: Celgene, Eli Lilly and Company, Galapagos, and Gilead, Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Roche, and UCB, Mart van de Laar Consultant of: Sanofi Genzyme, Speakers bureau: Sanofi Genzyme

DOI: 10.1136/annrheumdis-2020-eular.1219

THU0580

**EULAR TASK FORCE ON GENDER EQUITY IN ACADEMIC RHEUMATOLOGY: PRELIMINARY SURVEY FINDINGS**

P. V. Ovseiko<sup>1</sup>, L. Gossec<sup>1</sup>, L. Andreoli<sup>1</sup>, U. Kiltz<sup>1</sup>, L. Van Mens<sup>1</sup>, N. Hassan<sup>1</sup>, M. Van der Leeden<sup>1</sup>, H. J. Siddle<sup>1</sup>, A. Alunno<sup>1</sup>, I. McInnes<sup>1</sup>, N. Damjanov<sup>1</sup>, F. Apparailly<sup>1</sup>, C. Ospelt<sup>1</sup>, I. Van der Horst-Bruinsma<sup>1</sup>, E. Nikiphorou<sup>1</sup>, K. Druce<sup>1</sup>, Z. Szekanecz<sup>1</sup>, A. Sepriano<sup>1</sup>, T. Avcin<sup>1</sup>, G. Bertsias<sup>1</sup>, G. Schett<sup>1</sup>, A. M. Keenan<sup>1</sup>, L. C. Coates<sup>1</sup> on behalf of EULAR Task Force on Gender Equity in Academic Rheumatology. <sup>1</sup>EULAR Task Force on Gender Equity in Academic Rheumatology, Zürich, Switzerland

**Background:** Women represent an increasing proportion of the overall rheumatology workforce, but are underrepresented in academic rheumatology, especially in leadership roles [1].

**Objectives:** The EULAR Task Force on Gender Equity in Academic Rheumatology has been convened to establish the extent of the unmet need for support of female rheumatologists, health professionals and non-clinical scientists in academic rheumatology and develop a framework to address this through EULAR and EMEUNET.

**Methods:** To investigate gender equity in academic rheumatology, an anonymous web-based survey was targeted at the membership of EULAR and Emerging EULAR Network (EMEUNET) and their wider networks. The survey was developed based on a narrative literature review [1], best practice from The Association of Women in Rheumatology, a survey of task force members and face-to-face task force discussions. Personal experiences were explored and 24 potential interventions to aid career advancement were ranked. Statistics were descriptive with significance testing for male/female responses compared using chi-squared/t-tests. The level of significance was set at p<0.001.

**Results:** A total of 301 respondents from 24 countries fully completed the survey. By profession, 290 (86.4%) were rheumatologists, 19 (6.3%) health professionals, and 22 (7.3%) non-clinical scientists. By gender, 217 (72.1%) were women, 83 (27.6%) men, and 1 (0.3%) third gender. By age, 203 (67.5%) were 40 or under. By ethnicity, 30 (10.0%) identified themselves as ethnic minority. A high proportion of respondents reported having experienced gender discrimination (47.2% total: 58.1% for women and 18.1% for men) and sexual harassment (26.2%: 31.8% and 10.8% respectively) (Figure 1). Chi-squared tests on the numbers on which these proportions were based showed